List view / Grid view

# dexamethasone

### Melflufen increases refractory multiple myeloma survival in Phase III study

13 September 2021 | By

Melfufen met the primary endpoint of superior progression free survival (PFS) with a median of 6.8 months in Phase III OCEAN trial.

### Fostamatinib reduces COVID-19 risks by 50 percent in Phase II study

2 September 2021 | By

Fostamatinib significantly reduced serious adverse effects and risk of death in hospitalised COVID-19 patients, shows Phase II study.

### Achieving sustainable innovation with value-added medicines

26 August 2021 | By

The COVID-19 pandemic spotlighted drug repurposing as a key strategy to support traditional novel chemical entity development; yet repurposing is just one example of how off-patent molecules can be further developed to provide patients with more treatment options. Here, Arun Narayan, Chairman of the Value Added Medicines Sector Group at…

### How off-patent strategies benefit patient care

29 June 2021 | By

Graeme Duncan, CEO at ADVANZ PHARMA, discusses how targeted strategic investment within the off-patent sector can add value and enhance choice for patients and healthcare professionals alike, while helping to drive and maintain innovation within the pharmaceutical industry.

### Targeted drug delivery enabled by genetically engineered nanoparticles

17 June 2021 | By

In a pre-clinical study, researchers were able to genetically engineer cell membrane-coated nanoparticles to deliver dexamethasone directly to the inflamed lungs of mice.

### Remestemcel-L reduces ARDS mortality in those under 65 years old

4 May 2021 | By

New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS) were up to 75 percent less likely to die when treated with remestemcel-L and dexamethasone.

### Lenzilumab™ significantly improves survival in hospitalised COVID-19 patients

31 March 2021 | By

In a Phase III trial, adding Lenzilumab™ to steroid and remdesivir regimens improved the likelihood of survival without need for mechanical ventilation by 54 percent.

### Trial to compare dexamethasone and baricitinib in hospitalised COVID-19 patients

26 November 2020 | By

The fourth iteration of the COVID-19 treatment trial will determine whether remdesivir plus baricitinib or dexamethasone is more effective at promoting recovery from COVID-19.

### Availability of critical medicines during pandemics

23 October 2020 | By

The impact of COVID-19 is wide-reaching with disruptions to supply chains likely to continue over the coming years. In this article, Dave Elder discusses the effect of the pandemic on the supply and demand of critical medicines and what this means for pharma supply chains.

### EMA recommends seven medicines for approval after September meeting

22 September 2020 | By

Following its latest meeting, the EMA's CHMP has suggested granting marketing authorisation to seven medicines and extending the indications of 15 others.

### Phase III trial to study REGN-COV2, potential COVID-19 antibody treatment

16 September 2020 | By

REGN-COV2 will be evaluated alongside standard-of-care in a Phase III study as part of the COVID-19 RECOVERY trial.

### Dexamethasone Taw application to treat COVID-19 to be evaluated by EMA

8 September 2020 | By

Dexamethasone Taw will be examined by the EMA on an accelerated assessment timetable, to assess whether it should be given to patients with COVID-19.

### Interleukin-6 inhibitors improve outcomes for COVID-19 patients in study

5 August 2020 | By

Researchers have shown that symptoms in patients experiencing severe COVID-19 improved when given either sarilumab or tocilizumab, interleukin-6 inhibitors.

### EMA initiates review of dexamethasone for treating COVID-19

28 July 2020 | By

The EMA has begun to review dexamethasone to provide an opinion on the results of the RECOVERY study for the treatment of adults admitted to hospital with COVID-19.